CTi Biopharma Corp

Company Profile

CTi Biopharma Corp had its IPO on 1997-03-21 under the ticker symbol CTIC.

The company operates in the Healthcare sector and Biotechnology industry. CTi Biopharma Corp has a staff strength of 127 employees.

Stock update

Shares of CTi Biopharma Corp opened at $4.37 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $4.2 - $4.39, and closed at $4.34.

This is a -1.59% slip from the previous day's closing price.

A total volume of 6,475,100 shares were traded at the close of the day’s session.

In the last one week, shares of CTi Biopharma Corp have slipped by -4.41%.

CTi Biopharma Corp's Key Ratios

CTi Biopharma Corp has a market cap of $582.74 million, indicating a price to book ratio of 112.6329 and a price to sales ratio of 22.0081.

In the last 12-months CTi Biopharma Corp’s revenue was $53.95 million with a gross profit of $50.43 million and an EBITDA of $-69336000. The EBITDA ratio measures CTi Biopharma Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CTi Biopharma Corp’s operating margin was -132.14% while its return on assets stood at -44.92% with a return of equity of -1018.75%.

In Q4, CTi Biopharma Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 216.6%.

CTi Biopharma Corp’s PE and PEG Ratio

Forward PE

26.5957

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 26.5957 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CTi Biopharma Corp’s profitability.

CTi Biopharma Corp stock is trading at a EV to sales ratio of 20.1729 and a EV to EBITDA ratio of -6.6763. Its price to sales ratio in the trailing 12-months stood at 22.0081.

CTi Biopharma Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$125.93 million

Total Liabilities

$81.13 million

Operating Cash Flow

$537000.00

Capital Expenditure

$0

Dividend Payout Ratio

0%

CTi Biopharma Corp ended 2023 with $125.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $125.93 million while shareholder equity stood at $-17577000.00.

CTi Biopharma Corp ended 2023 with $0 in deferred long-term liabilities, $81.13 million in other current liabilities, 131000.00 in common stock, $-2518907000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $30.42 million and cash and short-term investments were $79.94 million. The company’s total short-term debt was $47,943,000 while long-term debt stood at $0.

CTi Biopharma Corp’s total current assets stands at $99.40 million while long-term investments were $0 and short-term investments were $49.52 million. Its net receivables were $15.39 million compared to accounts payable of $2.01 million and inventory worth $733000.00.

In 2023, CTi Biopharma Corp's operating cash flow was $537000.00 while its capital expenditure stood at $0.

Comparatively, CTi Biopharma Corp paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$4.34

52-Week High

$7.8

52-Week Low

$3.32

Analyst Target Price

$11.23

CTi Biopharma Corp stock is currently trading at $4.34 per share. It touched a 52-week high of $7.8 and a 52-week low of $7.8. Analysts tracking the stock have a 12-month average target price of $11.23.

Its 50-day moving average was $5.34 and 200-day moving average was $5.71 The short ratio stood at 5.74 indicating a short percent outstanding of 0%.

Around 18.8% of the company’s stock are held by insiders while 8183.7% are held by institutions.